{"id":833,"date":"2020-09-10T09:26:52","date_gmt":"2020-09-10T16:26:52","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=833"},"modified":"2020-09-11T09:27:40","modified_gmt":"2020-09-11T16:27:40","slug":"high-seroprevalence-of-anti-sars-cov-2-antibodies-in-chelsea-massachusetts","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/09\/10\/high-seroprevalence-of-anti-sars-cov-2-antibodies-in-chelsea-massachusetts\/","title":{"rendered":"High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts"},"content":{"rendered":"<p>\u2022\u00a0Among asymptomatic residents of Chelsea, Massachusetts without a prior positive PCR test for SARS-CoV-2 (n=200), the seroprevalence of SARS-CoV-2 antibodies was 32% (18% IgM+IgG+, 9% IgM+IgG-, and 5% IgM-IgG+), representing a substantial burden of undocumented infection. Additionally, 51% of participants reported no symptoms in the preceding 4 weeks, of whom 25% (25\/101) were seropositive, and 60% of these were IgM+IgG-.<\/p>\n<p><em>Naranbhai et al. (Sept 9, 2020). High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. The Journal of Infectious Diseases. <a href=\"http:\/\/discover.uw.edu\/P03080yAxQ00P10B0ZUOqA0\">https:\/\/doi.org\/10.1093\/infdis\/jiaa579<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u2022\u00a0Among asymptomatic residents of Chelsea, Massachusetts without a prior positive PCR test for SARS-CoV-2 (n=200), the seroprevalence of SARS-CoV-2 antibodies was 32% (18% IgM+IgG+, 9% IgM+IgG-, and 5% IgM-IgG+), representing a substantial burden of undocumented infection. Additionally, 51% of participants reported no symptoms in the preceding 4 weeks, of whom 25% (25\/101) were seropositive, and&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/09\/10\/high-seroprevalence-of-anti-sars-cov-2-antibodies-in-chelsea-massachusetts\/\">Read more<\/a><\/div>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[32,27],"topic":[19],"class_list":["post-833","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-immunity","tag-testing","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=833"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/833\/revisions"}],"predecessor-version":[{"id":834,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/833\/revisions\/834"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=833"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}